Results 11 to 20 of about 7,115 (194)

Enteropathy Associated with Olmesartan [PDF]

GE: Portuguese Journal of Gastroenterology, 2016
The recognition of an enteropathy caused by olmesartan is recent. It was first described in 2012 by the Mayo Clinic, which presented 22 clinical cases. Olmesartan is a highly prescribed drug and the differential diagnosis of a sprue-like enteropathy is ...
Bruno Moreira da Silva, Sofia Jardim Neves, Arantza Germade Martínez, Karina de Jesús Geneux, Jesús Lomas García, Sergio Maestro Antolín, Antonio Pérez Millán   +6 more
doaj   +4 more sources

Olmesartan-Induced Enteropathy [PDF]

Methodist DeBakey Cardiovascular Journal, 2016
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of olmesartan-induced enteropathy includes diarrhea, weight loss, and nausea. In contrast to celiac disease, tissue transglutaminase is not
Abimbola, Adike, Juan, Corral, David, Rybnicek, Daniel, Sussman, Samir, Shah, Eamonn, Quigley   +5 more
openaire   +3 more sources

Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy.

PLoS ONE, 2015
Background and objectivesAnti-hypertensive treatment with the angiotensin II receptor antagonist olmesartan is a rare cause of severe Sprue-like enteropathy. To substantiate the hypothesis that olmesartan interferes with gut immune homeostasis, clinical,
Sophie Scialom, Georgia Malamut, Bertrand Meresse, Nicolas Guegan, Nicole Brousse, Virginie Verkarre, Coralie Derrieux, Elizabeth Macintyre, Philippe Seksik, Guillaume Savoye, Guillaume Cadiot, Lucine Vuitton, Lysiane Marthey, Franck Carbonnel, Nadine Cerf-Bensussan, Christophe Cellier   +15 more
doaj   +2 more sources

Olmesartan medoxomil: current status of its use in monotherapy

Vascular Health and Risk Management, 2006
Hans R BrunnerLausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, SwitzerlandAbstract: Olmesartan medoxomil is an angiotensin II receptor antagonist.
Hans R Brunner
doaj   +1 more source

Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study

Vascular Health and Risk Management, 2011
Takeshi Takami1, Yoshihiko Saito21Department of Internal Medicine, Clinic Jingumae, Kashihara, Japan; 2First Department of Internal Medicine, Nara Medical University, Kashihara, JapanPurpose: The aim of this study was to compare the effects of olmesartan
Takami T, Saito
doaj   +1 more source

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension

Vascular Health and Risk Management, 2006
Mark GreathouseSouth Hills Cardiology Associates of Pittsburgh, Pittsburgh, PA, USAAbstract: In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When
Mark Greathouse
doaj   +1 more source

Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines

Clinical Interventions in Aging, 2015
Stefano Omboni,1 Ettore Malacco,2 Jean-Michel Mallion,3 Massimo Volpe4,5 1Clinical Research Unit, Italian Institute of Telemedicine, Solbiate Arno, Varese, Italy; 2Department of Internal Medicine, Ospedale L Sacco, University of Milan, Milan, Italy ...
Omboni S, Malacco E, Mallion JM, Volpe M
doaj   +1 more source

Hemorrhagic Cystitis With Bladder Tamponade Associated With <i>Morganella morganii</i> in an Older Patient Without Recent Catheterization. [PDF]

IJU Case Rep
ABSTRACT Introduction Morganella morganii is an uncommon cause of urinary tract infection, typically associated with catheterization or underlying diseases. Case Presentation I report a rare case of severe hemorrhagic cystitis with massive intravesical clot retention in a 90‐year‐old woman without recent catheterization or diabetes mellitus ...
Kawaguchi Y.
europepmc   +2 more sources

Olmesartan-Associated Enteropathy [PDF]

Baylor University Medical Center Proceedings, 2017
Olmesartan, an angiotensin-receptor blocker frequently prescribed for hypertension, has been commercially available since 2002. In 2012, olmesartan-associated enteropathy was described, and the Food and Drug Administration now requires a black-box warning for olmesartan regarding severe diarrhea.
Vivian S, Ebrahim, Jason, Martin, Stacey, Murthy, Elizabeth, Odstrcil, He, Huang, Daniel, Polter   +5 more
openaire   +2 more sources

Benzbromarone as a Novel Candidate for Preventing Alzheimer's Disease: Evidence From Real-World Data Screening and in Vitro Validation. [PDF]

Clin Transl Sci
Drug repositioning analysis identifies candidate therapeutic agents for Alzheimer’s diseaseand supports further mechanistic and translational investigation. ABSTRACT Drug development for Alzheimer's disease (AD) remains challenging, with only a 0.4% success rate from Phase I trials to regulatory approval.
Sakagami S, Yoshida Y, Uemura S, Kumamoto T, Tsukamoto R, Nishi T, Kawano S, Fukuoka K, Ino H, Hamamura K, Ohdo S, Matsunaga N.   +11 more
europepmc   +2 more sources